Table 3.

Dengue IgM and IgG seroprevalence and cross-reactivity for each rapid diagnostic test and each analyte in patients with nondengue infections

DiseaseTotal no. of samplesNo. of samples (%; 95% CI) with >15 units of:aNo. of samples (%; 95% CI) with cross-reactivity of:
IgM antibodies by indicated testNS1 antigens by indicated test
IgMIgGMerlinBiosynexStandard DiagnosticsPanbioStandard DiagnosticsBio-RadPanbio
Chikungunya822 (2.4; 1-8)22 (26.8; 18-37)25 (59.5; 44-73)47 (53.4; 43-63)10 (58.8; 36-78)15 (46.9; 31-64)1 (100)4 (36.4; 15-65)
Leptospirosis331 (3.0; 1-15)2 (6.1; 2-20)5 (11.9; 5-25)16 (18.2; 12-28)2 (11.8; 3-34)3 (9.4; 3-24)1 (50; 9-91)2 (18.2; 5-48)
Bacteremia1903 (15.8; 6-38)3 (7.1; 2-19)11 (12.5; 7-21)3 (9.4; 3-24)1 (50; 9-91)1 (9.1; 2-4)
Scrub typhus802 (25.0; 5-33)2 (4.8; 1-16)5 (5.7; 2-13)1 (5.9; 1-27)5 (15.6; 7-32)2 (18.2; 5-48)
Q fever701 (14.3; 3-51)2 (4.8; 1-16)2 (2.3; 1-8)1 (5.9; 1-27)3 (9.4; 3-24)2 (18.2; 5-48)
Tuberculosis4003 (7.1; 2-19)3 (3.4; 1-10)2 (11.8; 3-34)1 (3.1; 1-16)
Urinary tract infection501 (20.0; 4-62)2 (2.3; 1-8)
Malaria11 (100; 21-100)1 (100; 21-100)1 (2.4; 0-12)1 (1.1; 0-6)1 (5.9; 1-27)1 (3.1; 1-16)
Spotted fever1001 (2.4; 0-12)1 (1.1; 0-6)1 (3.1; 1-16)
Total1604 (2.5; 0-6)32 (20; 15-27)42 (26.3; 10-33)88 (55.0; 47-63)17 (10.6; 7-16)32 (20.0; 15-27)1 (0.63; 0-33)2 (1.3; 0-4)11 (6.9; 4-12)
  • a As determined by AFRIMS dengue ELISAs.